Provides consistent plasma concentrations compared to oral routes. The liver enzyme CYP2C9 plays a vital role in this conversion, which influences the drug’s onset and duration of action.
Ketorolac IV Versus IM Safety: Comparing Efficacy and Risks
The intramuscular dose is typically 30 mg to 60 mg, while the intravenous dose ranges from 15 mg to 30 mg, highlighting that dosing is weight-based and renal function-dependent. Consequently, the route selected can alter the time to peak plasma concentration and the overall bioavailability of the medication.
Bypasses first-pass metabolism in the gut, ensuring higher bioavailability. Similarly, liver disease can impede the metabolic conversion of the prodrug, altering the efficacy and safety profile, which underscores the importance of patient-specific assessment before administration.
Ketorolac IV Versus IM Safety: Comparing Systemic Effects and Dosing
While convenient, the oral bioavailability is significantly lower due to first-pass metabolism, resulting in a delayed onset of action. However, the IV route necessitates careful monitoring due to the potential for a more pronounced systemic effect compared to IM injection.
More About Ketorolac route of administration
Looking at Ketorolac route of administration from another angle can help expand the discussion and give readers a second clear paragraph under the same section.
More perspective on Ketorolac route of administration can make the topic easier to follow by connecting earlier points with a few simple takeaways.
